Highlights
- Record quarterly September 2025 revenue of AUD 3.0M, up 11% from previous quarter
- US market rollout progressing: 25-state distributor network covering 40% of population.
- OCC stock rises 9.7% to AUD 1.580 per share following strong results
Orthocell Limited (ASX:OCC) develops regenerative products for bone, soft tissue, and nerve repair. Key products include Striate+™ for dental applications and Remplir™ for nerve reconstruction.
Quarterly Revenue Growth
OCC has released its quarterly report for the period ended 30 September 2025, reporting record revenue of AUD 3.0M. This represents an 11% increase over the previous quarterly record of AUD 2.7M in June 2025 and a 50% increase from AUD 2.0M in September 2024. The result marks the sixth consecutive quarter of record revenue, with a Compound Quarterly Growth Rate (CQGR) of 11% since Q2 FY24.
Revenue growth during the quarter was primarily driven by Remplir’s expanding market penetration in Australia and Singapore. The report notes that this revenue does not yet include significant contributions from the US market, which are expected to increase in the December 2025 Quarter and into the second half of FY26.
US and Canadian Market Rollout
Orthocell has advanced its commercialisation of Remplir in the US, a market valued at USD 1.6B for nerve repair. The first US surgeries have been completed in multiple hospitals, with over 100 surgeons introduced to the product, and 14 Medical Advisory Board members under contract.
During the quarter, 51 Value Analysis Committee (VAC) applications were lodged with hospitals, with 11 approvals already in place, and state licenses are in progress. Orthocell appointed its first Canadian distributor (USD 75M), covering Alberta and British Columbia, with initial sales expected in the December 2025 Quarter
Clinical Applications and Study Results
Remplir was used in nerve-sparing prostate cancer surgeries, with 40 surgical cases completed in Australia. Initial patient data is expected in Q4 CY25. The product achieved an 81% success rate in practical studies, effectiveness in reconnecting severed nerves, protecting damaged nerves, or capping nerve ends after amputation.
Corporate Updates
Orthocell strengthened its leadership team with the appointments of Jim Piper as CFO and Adam Wood as CCO. Michael McNulty, former Managing Partner of Deloitte’s Perth office, joined the Board as a Non-Executive Director following the retirement of The Hon Kim Beazley AC for health reasons.
CEO and MD Paul Anderson stated:
"We have continued to build strong commercial momentum in the September quarter with another record quarter of sales revenue delivered primarily from Remplir sales in our existing markets in Australia and Singapore. The US rollout of Remplir remains a central operational focus and pleasingly we’re well ahead of schedule in this regard. We’ve seen the first revenue contributions from the US during the quarter from our early surgical cases, and we expect that to build during the December 2025 Quarter and grow into the second half of the financial year.”
Financial Position
Cash receipts from customers totaled AUD 2.4M for the quarter, while net cash outflows from operating activities were AUD 3.0M, primarily directed toward manufacturing, commercial, and R&D activities. Orthocell held a cash balance of AUD 27M at quarter-end, supporting ongoing sales growth and international expansion initiatives.
Share Performance of OCC
The company’s stock is trading at AUD 1.580 per share, an increase of 9.722% from the previous close of AUD 1.440.






Please wait processing your request...